ORLANDO, FL, USA (UroToday.com) - The authors reported the final results from the bevacizumab plus interferon vs. interferon alone trial for patients with metastatic renal cell carcinoma (mRCC).
Your session will expire in 8 hours requiring you to log in each day to view content.